Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Small molecule drug discovery targeting rare genetic diseases and oncology
Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic…
Global biopharma with UK manufacturing, commercial and clinical operations
MSD is a global biopharmaceutical company discovering, developing, manufacturing and marketing medicines and vaccines across oncology, infectious disease, immunology, cardiometabolic disease and animal health. Its UK operations span pharmaceutical manufacturing at Cramlington, Northumberland, which supplies medicines…
Drug discovery platform targeting biomolecular condensates
Transition Bio is a biotechnology company developing a drug discovery platform based on the biology of biomolecular condensates, the membrane-less cellular structures implicated in a range of diseases. Using droplet microfluidics and machine learning, the company maps and modulates condensate behaviour to identify…
One-step encapsulation drug delivery platform for advanced therapeutics
PNAS Therapeutics is a UK-based drug delivery company developing a one-step encapsulation platform designed to simplify complex pharmaceutical manufacturing processes. The platform enhances local delivery through improved bioavailability and targeting, is compatible with multiple active pharmaceutical ingredients, and…
Preventing cancer therapy side effects with topical medicines
VasoDynamics is a clinical-stage pharmaceutical development company focused on preventing the debilitating side effects of cancer therapy. The company develops topical formulations targeting radiation-induced oral mucositis, dermatitis, and chemotherapy-induced hair loss, using vasoconstrictor and radioprotective…
Discovery platform targeting therapy-induced antigens driving cancer relapse
Errigal Bio is an oncology-focused drug discovery company developing a platform that identifies therapy-induced antigen targets arising in cancer cells that survive standard treatment. The company's approach is based on the premise that these surviving tumour cells carry exploitable vulnerabilities created by the…
High-sensitivity lateral flow diagnostics for point-of-care testing
SwiftDx is a Cambridge-based diagnostics company developing a next generation of high-sensitivity lateral flow assays using proprietary eAMP (enhanced Amplification) and DNA detection technologies. Its platform enables detection of targets undetectable by conventional lateral flow tests, without requiring specialist…
CRO specialising in oncology, inflammation and respiratory disease models
Axis Bioservices is a preclinical contract research organisation providing bespoke in vitro and in vivo study services for pharmaceutical, biotechnology and academic clients. Specialist capabilities span oncology tumour models, inflammatory disease models including rheumatoid arthritis and pulmonary fibrosis, and…
Fibroblast immunology platform targeting cancer and inflammatory disease
Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies that target activated fibroblasts to modulate immune responses in cancer and inflammatory disease. Its lead programme, MST-0312, is a FAP-targeted LTBR agonist bispecific antibody designed to induce tertiary…
Small-molecule HO-1 inhibitors to overcome chemotherapy resistance in tumours
Aethox Therapeutics is a preclinical biotechnology company developing small-molecule drugs that help solid tumours respond to chemotherapy and other standard cancer treatments. Its lead approach targets heme oxygenase-1 (HO-1), an enzyme produced by tumour-associated macrophages that can block cancer-fighting T cells…
Next-generation lateral CAR-T therapies for refractory solid tumours
Leucid Bio Ltd is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for hard-to-treat solid tumours. Founded on over two decades of King's College London research, the platform redesigns the CAR signalling architecture to enhance T-cell potency, persistence, and tumour…
Target discovery platform and antibody-based therapies for oncology
Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies,…
UK affiliate of global family-owned biopharmaceutical company
Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates…
Antibody discovery platform identifying therapeutics from resilient individuals
Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology. Its platform combines deep B cell sequencing and machine learning to identify naturally protective antibodies from individuals resilient to specific diseases.…
Small molecule inhibitors targeting APOBEC enzymes in cancer
Apobec Discovery is a preclinical-stage biotechnology company developing first-in-class small molecule inhibitors of APOBEC3A and APOBEC3B, cytidine deaminase enzymes that drive tumour mutagenesis, evolution, and resistance to treatment. By blocking APOBEC activity, the company aims to limit the mutational capacity of…
Clinical-stage antibody-drug conjugate developer for cancer
Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat cancers. Its platform combines stable bioconjugation chemistry with tumour-selective payload activation to improve therapeutic index. Clinical programmes include IKS014, a HER2-targeting ADC, and…
Engineered cell-derived vesicles for targeted RNA and drug delivery
AAB Therapeutics develops programmable nanovesicles from engineered human cell membranes for targeted intracellular drug delivery. The vesicles are designed to carry RNA, small molecules or biologics, using surface targeting molecules and fusogenic proteins to release their cargo into cells. The preclinical company…
World's largest independent cancer research funder and charity
Cancer Research UK is a registered charity and the world's largest independent funder of cancer research, supporting over 4,000 researchers, doctors and nurses across the UK. The organisation funds basic laboratory research, drug discovery, clinical trials, prevention and early detection science. It operates four core…
Antibody fragment drug conjugate platform for solid tumour oncology
Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours. The company's proprietary platform uses smaller antibody fragments rather than whole antibodies to achieve improved tumour penetration and faster systemic clearance compared…
ECM-targeted drug discovery platform for fibrosis and solid tumours
Engitix is a preclinical-stage biotechnology company developing therapeutics that target the extracellular matrix (ECM) in fibrosis and solid tumours. Its proprietary discovery platform integrates one of the largest ECM bioarchives with AI and machine learning to identify disease-specific targets and biomarkers.…